Navigation Links
WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division
Date:7/24/2014

PRINCETON, N.J., July 24, 2014 /PRNewswire/ -- WIRB-Copernicus Group® ("WCG")™, the world's largest provider of regulatory and ethical review services for clinical research, announced today that it has acquired Alliance Biosciences. Formerly a division of Richmond, VA-based Alliance Engineering, Alliance Biosciences was the leading biosafety and biosecurity consulting firm in the United States. With this addition, WCG's biosafety division – WCG Biosafety™ – will be able to manage the entire continuum of biosafety oversight, helping to ensure that research involving potentially hazardous agents and vectors complies with the appropriate safety and regulatory requirements from laboratory design and drug discovery through clinical testing and therapeutic application.

"Recent news headlines regarding the mishandling of smallpox virus, avian influenza virus, and anthrax bacteria by government healthcare agencies underscore the importance of biosafety oversight for the public as well as industry professionals," said WCG Chairman & Chief Executive Officer Donald A. Deieso, Ph.D. "With this expansion to our WCG Biosafety team, we can now oversee all aspects of the biosafety review process from building the laboratories and organizing materials to managing the regulatory review boards and ethical approval process for drugs in development."

"My colleagues and I are tremendously proud to join WCG, and to expand our service offering to create a unified, seamless biosafety solution," said Ryan Burnette, Ph.D., former director of Alliance Biosciences and newly-appointed vice president of WCG Biosafety. "Biological science is a driving force in our society.  As the promise of gene therapy increases, vaccine development expands, and the industry continues to explore new applications for infectious agents, the need for biosafety and biosecurity is more important than ever. We can make a greater impact as part of an organization that has for its mission the advancement of science and the protection of life." 

The most experienced provider of biosafety solutions, WCG Biosafety manages more than 200 Institutional Biosafety Committees (IBCs) and has evaluated more than 140 gene transfer clinical and recombinant DNA pre-clinical research protocols to date. That is more reviews than any other U.S. organization outside of the Food and Drug Administration and the National Institutes of Health. IBCs are considered the cornerstone of the oversight process for any research involving recombinant and synthetic nucleic acid – gene therapies – at the institutions where the studies are being conducted.

WCG Biosafety brings together the leading authorities in biosafety, biosecurity, and bio-risk management to provide comprehensive review services and consulting solutions to government organizations, pharma and biotech companies, private research organizations, and academic institutions around the world.

WCG Biosafety helps these organizations to ensure the protection of human subjects, the safety of their investigators and personnel, and the security of their laboratories and workspaces. In addition to providing administrative support and mentoring for IBCs and biosafety officers, WCG Biosafety also specializes in containment laboratory design (BSL-1/2/3/4) guidance, facility evaluations, documentation and program audits, risk/threat assessments, and custom biosafety training.

Jenna Hess, M.S., who was formerly deputy director at Alliance Biosciences, has also joined WCG Biosafety as the division's director of operations.

About the WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's largest provider of regulatory and ethical solutions for clinical research, including Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review. The pioneer of independent ethical oversight, WCG continues to drive progress in the clinical research space. Today, WCG's solutions are built upon the foundation of ethical review, but have grown to include a suite of complementary services and technologies. These offerings include electronic informed-consent solutions, interactive Part 11-compliant online learning management solutions for clinical research professionals, and software compliance and research oversight solutions for institutions. WCG leverages its industry insight to stimulate growth, foster compliance, and maximize efficiency for those who perform clinical trials.

For more information, please visit www.wcgclinical.com or follow us on Twitter @WCGClinical.

Logo - http://photos.prnewswire.com/prnh/20140422/77410


'/>"/>
SOURCE WIRB-Copernicus Group
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. WIRB-Copernicus Group Leaders Speak at Global Clinical Research Summit in South Korea
2. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
3. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
4. BioNeutral Group Receives $400,000 in Equity Financing
5. MiMedx Group Completes $5,000,000 Private Placement
6. Use Biomarkers in Alzheimers Disease Clinical Trials, Says Expert Group
7. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
8. Lend Lease Announces the Appointment of Tom Chapman as Director Operations for the Life Sciences Group in the Atlantic Region
9. Statewide Network of Angel Investor Groups Announced in Alabama
10. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on Wednesday, March 7, 2012
11. Weikang Bio-Technology Group Co., Inc. Is Expected to Achieve the Net Profit of at Least $26 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical , ... designed to target cancer stemness pathways, will feature data ... napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, held ... . Napabucasin is an orally-administered investigational ... STAT3. i Cancer stem cells (CSCs) possess the ...
(Date:1/18/2017)... HACKENSACK, N.J. , Jan. 18, 2017   ... leading the fight to end Duchenne muscular dystrophy ... awarded to the New Jersey Institute of Technology (NJIT) ... ongoing exploration of robotic technology to assist ... study to incorporate NJIT,s technology – an embedded computer, ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total Orthopedics and Sports ... A-CIFT™ Solofuse-P™. The operation took place on Wednesday, January 11, 2017 at Long ... an anterior cervical discectomy and fusion on a 42 year old female who ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... new federally funded bio-focused Manufacturing Innovation Institutes (MII). U.S. Secretary of Commerce Penny ... Manufacturing Biopharmaceuticals (NIIMBL), and the Department of Defense has announced the award of ...
Breaking Biology Technology:
(Date:12/20/2016)... 20, 2016   Valencell , the leading ... STMicroelectronics (NYSE: STM), a global semiconductor leader ... announced today the launch of a new, highly ... that includes ST,s compact SensorTile turnkey ... biometric sensor system. Together, SensorTile and Benchmark deliver ...
(Date:12/16/2016)... global wearable medical device market, in terms of value, is projected ... in 2016, at a CAGR of 18.0% during the forecast period. ... Growth in ... launch of a growing number of smartphone-based healthcare apps compatible with ... increasing focus on physical fitness. Furthermore, growing trend ...
(Date:12/15/2016)... LONDON , Dec. 15, 2016 /PRNewswire/ ... the driving experience, health wellness and wellbeing ... As one in three new passenger vehicles ... voice recognition, gesture recognition, heart beat monitoring, ... eyelid monitoring, facial monitoring, and pulse detection. ...
Breaking Biology News(10 mins):